Novo's Obesity Drug Achieves 25% Weight Loss in Women in Late-Stage Trial | Retatrutide News

Novo Nordisk's new obesity drug achieved 25% weight loss in women during a late-stage trial. This result highlights the potential of GLP-1 agonists, whi...
Clinical Trials · October 20, 2026